Scarica l'app Stockscreener
8.27
3.16%
-0.27
Precedente Chiudi:
$8.54
Aprire:
$8.54
Volume 24 ore:
423.16K
Relative Volume:
0.52
Capitalizzazione di mercato:
$533.59M
Reddito:
$89.40M
Utile/perdita netta:
$-221.30M
Rapporto P/E:
-2.5396
EPS:
-3.2564
Flusso di cassa netto:
$-256.90M
1 W Prestazione:
-1.43%
1M Prestazione:
+18.48%
6M Prestazione:
-31.48%
1 anno Prestazione:
+4.82%
Intervallo 1D:
$8.13
$8.54
Intervallo di 1 settimana:
$8.10
$8.90
Portata 52W:
$6.055
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
8.27 | 533.59M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-10-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-09-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Protein Degrader Therapeutics (PROTACs & Molecular Glues) - openPR.com
Form 144 ARVINAS For: 9 July By Investing.com - Investing.com Nigeria
Morgan Stanley (ARVN) broker files Form 144 to sell 24,000 shares - Stock Titan
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Trading the Move, Not the Narrative: (ARVN) Edition - Stock Traders Daily
Arvinas Inc. (ARVN) Q1 2026 Earnings: Narrower Loss Surpasses ExpectationsRevenue Recognition Risk - dars.gov.et
ARVNArvinas Inc Latest SEC Filings - Finviz
ARVN News | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Form 4 Arvinas Inc For: 26 June By Investing.com - Investing.com South Africa
Arvinas (NASDAQ: ARVN) director receives RSU and option grants in new Form 4 - Stock Titan
Arvinas (ARVN) director receives RSU and stock option grants in equity award - Stock Titan
Arvinas (ARVN) director Briggs Morrison granted RSUs and stock options - Stock Titan
[Form 4] ARVINAS, INC. Insider Trading Activity - Stock Titan
Arvinas (ARVN) director receives new RSU and stock option awards - Stock Titan
Director Linda Bain receives RSUs and stock options at Arvinas (ARVN) - Stock Titan
Arvinas Inc (ARVN) Institutional Confidence - TradingKey
Arvinas, Inc. (NASDAQ: ARVN) Files Form 8-K: Key Company Details, Stock Info, and Compliance Disclosures (June 24, 2026) – Minichart - Minichart
Arvinas Inc (ARVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arvinas, Inc. Actuals & Estimates (NASDAQ:ARVN) - TradingView
Arvinas Shareholders Back Directors, Pay and Auditor Choices - TipRanks
Arvinas (NASDAQ: ARVN) investors back directors, pay and auditor - Stock Titan
ARVN Forecast — Price Target — Prediction for 2027 - TradingView
Arvinas CFO Andrew Saik sells $46,473 in company stock - Investing.com UK
Form 4 Arvinas Inc For: 24 June By Investing.com - Investing.com Nigeria
Arvinas CFO Andrew Saik sells $46,473 in company stock By Investing.com - Investing.com Australia
ARVINAS (ARVN) CFO auto-sells shares to cover RSU tax withholding - Stock Titan
(ARVN) Volatility Zones as Tactical Triggers - Stock Traders Daily
ARVN: All voting items passed at the virtual meeting, with no shareholder questions submitted - TradingView
Arvinas, Inc. (ARVN) reports Q1 loss, misses revenue estimates - MSN
Form 144 Arvinas Inc For: 23 June By Investing.com - Investing.com South Africa
Arvinas (NASDAQ: ARVN) to settle 5,846 vested RSU shares on 06/24/2026 - Stock Titan
Arvinas Announces Chief Medical Officer Leadership Transition - The Globe and Mail
Arvinas chief medical officer to depart amid company transition - Hartford Business Journal
[8-K] ARVINAS, INC. Reports Material Event - Stock Titan
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):